Pan Ebola vaccine innovative approach
PEVIA logo


Start Date
End Date
IMI2 - Call 8
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
6 189 570
EFPIA in kind
6 068 591
5 473 237
Total Cost
17 731 398


The devastating Ebola outbreak that struck western Africa in 2014-2016 left over 11 000 dead, including many medical workers. The outbreak highlighted the urgent need for safe, effective vaccines against the highly infectious disease.

There are a number of promising Ebola vaccines in development, and studies suggest that they are both safe and effective. Nevertheless, their large-scale deployment could be limited by issues such as the fact that they need to be stored at extremely low temperatures (-80°C). The goal of the PEVIA project is to develop second generation Ebola vaccines based on the proteins found on the surface of the virus. The project team is using the prime-boost approach, in which one vaccine is given to prime the immune system, and a second (different) vaccine is given to boost the immune response. The project hopes that the resulting regimen will be better suited to large-scale vaccination programmes in sub-Saharan countries, most notably because it will not require storage at low temperatures. In addition, PEVIA aims to develop innovative tools and methods to facilitate the development of new vaccine candidates for Ebola and related diseases, as well as novel diagnostic tests that can be deployed in the field.

Participants Show participants on map

EFPIA companies
  • Vaxeal Research, Evry, France
Universities, research organisations, public bodies, non-profit groups
  • Assistance Publique Hopitaux De Paris, Paris, France
  • Bernhard-Nocht-Institut Fuer Tropenmedizin, Hamburg, Germany
  • Centre Hospitalier Regional Et Universitaire De Lille, Lille, France
  • Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
  • Centre National De La Recherche Scientifique Cnrs, Paris, France
  • Commissariat A L Energie Atomique Et Aux Energies Alternatives, Paris, France
  • Ifakara Health Institute Trust, Dar es Salaam, Tanzania (United Republic of)
  • Istituto Nazionale Per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura A Carattere Scientifico, Rome, Italy
  • Istituto Superiore Di Sanita, Roma, Italy
  • Leibniz-Institut Fur Virologie, Hamburg, Germany
  • Universite D'Abomey-Calavi, Cotonou, Benin
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Excellgene SA, Monthey, Switzerland
  • Oligovax, Paris, France
Third parties
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France
Project coordinator
Marie-José Fleury
Assistance Publique Hopitaux De Paris